WO2012010849A3 - Methods of diagnosis and vaccines - Google Patents

Methods of diagnosis and vaccines Download PDF

Info

Publication number
WO2012010849A3
WO2012010849A3 PCT/GB2011/001104 GB2011001104W WO2012010849A3 WO 2012010849 A3 WO2012010849 A3 WO 2012010849A3 GB 2011001104 W GB2011001104 W GB 2011001104W WO 2012010849 A3 WO2012010849 A3 WO 2012010849A3
Authority
WO
WIPO (PCT)
Prior art keywords
vaccines
diagnosis
methods
polypeptides
mycoplasma
Prior art date
Application number
PCT/GB2011/001104
Other languages
French (fr)
Other versions
WO2012010849A2 (en
Inventor
Emily Ngaire Barker
Iain Robertson Peters
Christopher Richard Helps
Séverine TASKER
Original Assignee
University Of Bristol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Bristol filed Critical University Of Bristol
Publication of WO2012010849A2 publication Critical patent/WO2012010849A2/en
Publication of WO2012010849A3 publication Critical patent/WO2012010849A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/30—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56933—Mycoplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/30—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]

Abstract

The invention relates to immunogenic polypeptides from Mycoplasma haemofelis (Mhf) and 'Candidatus Mycoplasma haemominutum' (CMhm), and their use as vaccines and as markers of infection in the cat. The polypeptides are dnaK, gapA, pgk and EF-Ts.
PCT/GB2011/001104 2010-07-23 2011-07-22 Methods of diagnosis and vaccines WO2012010849A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36700110P 2010-07-23 2010-07-23
US61/367,001 2010-07-23

Publications (2)

Publication Number Publication Date
WO2012010849A2 WO2012010849A2 (en) 2012-01-26
WO2012010849A3 true WO2012010849A3 (en) 2012-05-03

Family

ID=44503979

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2011/001104 WO2012010849A2 (en) 2010-07-23 2011-07-22 Methods of diagnosis and vaccines

Country Status (1)

Country Link
WO (1) WO2012010849A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999014317A1 (en) * 1997-09-19 1999-03-25 Synbiotics Corporation Methods for the diagnosis of feline infectious anemia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999014317A1 (en) * 1997-09-19 1999-03-25 Synbiotics Corporation Methods for the diagnosis of feline infectious anemia

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ALLEMAN A RICK ET AL: "Western immunoblot analysis of the antigens of Haemobartonella felis with sera from experimentally infected cats", JOURNAL OF CLINICAL MICROBIOLOGY, vol. 37, no. 5, May 1999 (1999-05-01), pages 1474 - 1479, XP002662570, ISSN: 0095-1137 *
BARKER EMILY N ET AL: "Complete genome sequence of Mycoplasma haemofelis, a hemotropic mycoplasma.", JOURNAL OF BACTERIOLOGY APR 2011 LNKD- PUBMED:21317334, vol. 193, no. 8, April 2011 (2011-04-01), pages 2060 - 2061, XP002662576, ISSN: 1098-5530 *
BERENT LINDA M ET AL: "Physical map and genome sequencing survey of Mycoplasma haemofelis (Haemobartonella felis).", INFECTION AND IMMUNITY JUN 2003 LNKD- PUBMED:12761157, vol. 71, no. 6, June 2003 (2003-06-01), pages 3657 - 3662, XP002662574, ISSN: 0019-9567 *
DATABASE UniProt [Online] 1 March 2003 (2003-03-01), "RecName: Full=Elongation factor Ts; Short=EF-Ts;", XP002662572, retrieved from EBI accession no. UNIPROT:Q8EUG8 Database accession no. Q8EUG8 *
DATABASE UniProt [Online] 15 December 2003 (2003-12-15), "RecName: Full=Elongation factor Ts; Short=EF-Ts;", XP002662573, retrieved from EBI accession no. UNIPROT:Q7NC21 Database accession no. Q7NC21 *
HOELZLE K ET AL: "Vaccination with the Mycoplasma suis recombinant adhesion protein MSG1 elicits a strong immune response but fails to induce protection in pigs", VACCINE, ELSEVIER LTD, GB, vol. 27, no. 39, 27 August 2009 (2009-08-27), pages 5376 - 5382, XP026614438, ISSN: 0264-410X, [retrieved on 20090709], DOI: 10.1016/J.VACCINE.2009.06.072 *
JORES J ET AL: "Analysis of the immunoproteome of Mycoplasma mycoides subsp. mycoides small colony type reveals immunogenic homologues to other known virulence traits in related Mycoplasma species", VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, ELSEVIER BV, AMSTERDAM, NL, vol. 131, no. 3-4, 15 October 2009 (2009-10-15), pages 238 - 245, XP026600304, ISSN: 0165-2427, [retrieved on 20090503], DOI: 10.1016/J.VETIMM.2009.04.016 *
MESSICK JOANNE B ET AL: "Complete genome sequences of two hemotropic mycoplasmas, Mycoplasma haemofelis strain Ohio2 and Mycoplasma suis Strain Illinois.", JOURNAL OF BACTERIOLOGY APR 2011 LNKD- PUBMED:21317328, vol. 193, no. 8, April 2011 (2011-04-01), pages 2068 - 2069, XP002662577, ISSN: 1098-5530 *
MUSEUX KRISTINA ET AL: "In vivo transmission studies of 'Candidatus Mycoplasma turicensis' in the domestic cat.", VETERINARY RESEARCH 2009 SEP-OCT LNKD- PUBMED:19505421, vol. 40, no. 5, September 2009 (2009-09-01), pages 45, XP002662571, ISSN: 0928-4249 *
PETERS IAIN R ET AL: "Antigen specificity of the humoral immune response to Mycoplasma haemofelis infection.", CLINICAL AND VACCINE IMMUNOLOGY : CVI AUG 2010 LNKD- PUBMED:20519443, vol. 17, no. 8, 2 June 2010 (2010-06-02), pages 1238 - 1243, XP002662569, ISSN: 1556-679X *
SANTOS ANDREA P ET AL: "Genome of Mycoplasma haemofelis, unraveling its strategies for survival and persistence.", VETERINARY RESEARCH 2011 JAN-FEB LNKD- PUBMED:21936946, vol. 42, no. 1, January 2011 (2011-01-01), pages 102, XP002662575, ISSN: 0928-4249 *

Also Published As

Publication number Publication date
WO2012010849A2 (en) 2012-01-26

Similar Documents

Publication Publication Date Title
WO2014176373A3 (en) Interleukin-10 compositions and uses thereof
WO2011110655A3 (en) Immunogenic composition or vaccine against gram - negative bacterial, for example neiserial, infection or disease
CA2865011C (en) Methods and compositions for treating huntington's disease
WO2015138357A3 (en) Compositions useful in treatment of otc deficency
DK2707393T3 (en) FUSION PROTEINS AND COMBINATION VACCINES COVERING HAEMOPH-ILUS INFLUENZAE PROTEIN E AND PILIN A
WO2010069532A8 (en) Antibodies against human angiopoietin 2
WO2012104275A3 (en) Nanoparticles delivery systems, preparation and uses thereof
EP3626253A3 (en) Stable formulations of linaclotide
WO2009156960A3 (en) Novel adjuvant compositions
WO2016060996A3 (en) Interleukin-15 compositions and uses thereof
EP2827837B8 (en) Exopolysaccharide for the treatment and/or care of the skin, mucous membranes and/or nails
ZA201200832B (en) Immunogenic composition comprising antigenic s. aureus proteins
EP2576578A4 (en) Polymorphs of 2'-o-fucosyllactose and producing thereof
MY158992A (en) Forms of rifaximin and uses thereof
EP3845241A8 (en) Long lasting effect of new botulinum toxin formulations
WO2011140595A3 (en) Immunostimulatory and vaccine compositions
BRPI0816330A2 (en) Polypeptide composition, method for producing polypeptide composition, polypeptide construct, method for producing a polypeptide construct, nucleic acid construct, medicament or vaccine composition, method for producing a medicament or vaccine composition, and use of the polypeptide composition , a polypeptide construct, a nucleic acid construct or a medicament or vaccine composition
EP2471926A3 (en) Immunostimulatory oligodeoxynucleotides
WO2013057570A3 (en) Acrylic polymer formulations
MX347734B (en) S100a4 antibodies and therapeutic uses thereof.
WO2009009759A3 (en) Yersinia pestis antigens, vaccine compositions, and related methods
WO2012083302A3 (en) Compositions and methods for the treatment or prevention of human adenovirus-36 infection
WO2011141488A3 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
WO2012087327A3 (en) Polymer systems
SG178904A1 (en) Combination vaccines against respiratory tract diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11746601

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11746601

Country of ref document: EP

Kind code of ref document: A2